Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9626198rdf:typepubmed:Citationlld:pubmed
pubmed-article:9626198lifeskim:mentionsumls-concept:C0006142lld:lifeskim
pubmed-article:9626198lifeskim:mentionsumls-concept:C1516231lld:lifeskim
pubmed-article:9626198lifeskim:mentionsumls-concept:C0007226lld:lifeskim
pubmed-article:9626198lifeskim:mentionsumls-concept:C0476089lld:lifeskim
pubmed-article:9626198lifeskim:mentionsumls-concept:C0015127lld:lifeskim
pubmed-article:9626198lifeskim:mentionsumls-concept:C0039286lld:lifeskim
pubmed-article:9626198lifeskim:mentionsumls-concept:C0441471lld:lifeskim
pubmed-article:9626198lifeskim:mentionsumls-concept:C1314792lld:lifeskim
pubmed-article:9626198lifeskim:mentionsumls-concept:C0026565lld:lifeskim
pubmed-article:9626198lifeskim:mentionsumls-concept:C0038952lld:lifeskim
pubmed-article:9626198lifeskim:mentionsumls-concept:C0332189lld:lifeskim
pubmed-article:9626198lifeskim:mentionsumls-concept:C0936012lld:lifeskim
pubmed-article:9626198lifeskim:mentionsumls-concept:C1522673lld:lifeskim
pubmed-article:9626198lifeskim:mentionsumls-concept:C0441988lld:lifeskim
pubmed-article:9626198pubmed:issue6lld:pubmed
pubmed-article:9626198pubmed:dateCreated1998-7-1lld:pubmed
pubmed-article:9626198pubmed:abstractTextThis study provides estimates of the effect of tamoxifen treatment on mortality from four conditions known to be affected by tamoxifen in women who survive their breast cancer: contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic events. These estimates are in addition to tamoxifen's impact on primary breast cancer mortality.lld:pubmed
pubmed-article:9626198pubmed:languageenglld:pubmed
pubmed-article:9626198pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9626198pubmed:citationSubsetIMlld:pubmed
pubmed-article:9626198pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9626198pubmed:statusMEDLINElld:pubmed
pubmed-article:9626198pubmed:monthJunlld:pubmed
pubmed-article:9626198pubmed:issn0732-183Xlld:pubmed
pubmed-article:9626198pubmed:authorpubmed-author:RagazJJlld:pubmed
pubmed-article:9626198pubmed:authorpubmed-author:ColdmanAAlld:pubmed
pubmed-article:9626198pubmed:issnTypePrintlld:pubmed
pubmed-article:9626198pubmed:volume16lld:pubmed
pubmed-article:9626198pubmed:ownerNLMlld:pubmed
pubmed-article:9626198pubmed:authorsCompleteYlld:pubmed
pubmed-article:9626198pubmed:pagination2018-24lld:pubmed
pubmed-article:9626198pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:9626198pubmed:meshHeadingpubmed-meshheading:9626198-...lld:pubmed
pubmed-article:9626198pubmed:meshHeadingpubmed-meshheading:9626198-...lld:pubmed
pubmed-article:9626198pubmed:meshHeadingpubmed-meshheading:9626198-...lld:pubmed
pubmed-article:9626198pubmed:meshHeadingpubmed-meshheading:9626198-...lld:pubmed
pubmed-article:9626198pubmed:meshHeadingpubmed-meshheading:9626198-...lld:pubmed
pubmed-article:9626198pubmed:meshHeadingpubmed-meshheading:9626198-...lld:pubmed
pubmed-article:9626198pubmed:meshHeadingpubmed-meshheading:9626198-...lld:pubmed
pubmed-article:9626198pubmed:meshHeadingpubmed-meshheading:9626198-...lld:pubmed
pubmed-article:9626198pubmed:meshHeadingpubmed-meshheading:9626198-...lld:pubmed
pubmed-article:9626198pubmed:meshHeadingpubmed-meshheading:9626198-...lld:pubmed
pubmed-article:9626198pubmed:meshHeadingpubmed-meshheading:9626198-...lld:pubmed
pubmed-article:9626198pubmed:meshHeadingpubmed-meshheading:9626198-...lld:pubmed
pubmed-article:9626198pubmed:meshHeadingpubmed-meshheading:9626198-...lld:pubmed
pubmed-article:9626198pubmed:meshHeadingpubmed-meshheading:9626198-...lld:pubmed
pubmed-article:9626198pubmed:meshHeadingpubmed-meshheading:9626198-...lld:pubmed
pubmed-article:9626198pubmed:year1998lld:pubmed
pubmed-article:9626198pubmed:articleTitleSurvival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes.lld:pubmed
pubmed-article:9626198pubmed:affiliationDepartment of Medical Oncology, British Columbia Cancer Agency, Vancouver, Canada. jragaz@bccancer.bc.calld:pubmed
pubmed-article:9626198pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9626198pubmed:publicationTypeClinical Triallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9626198lld:pubmed